Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 27:18:14913-14926.
doi: 10.2147/JIR.S539644. eCollection 2025.

Temporal Relationship Between Visceral Fat and Inflammation, and Their Joint Effect on Cardiometabolic Diseases: Evidence from the China Health and Retirement Longitudinal Study (CHARLS)

Mengyue Lin #  1   2   3 , Yilian Zhou #  4 , Ruijie Wu  1   5 , Shaobin Li  1   2 , Xiaobin Ni  1 , Jiaxin Xiao  1 , Sirui Han  1   5 , Haoxian Tang  1   2 , Jieshan Huang  1   5 , Jiasheng Wen  1   2 , Liwen Jiang  1   2 , Xuerui Tan  1   2   3   6 , Yequn Chen  1   3   6
Affiliations

Temporal Relationship Between Visceral Fat and Inflammation, and Their Joint Effect on Cardiometabolic Diseases: Evidence from the China Health and Retirement Longitudinal Study (CHARLS)

Mengyue Lin et al. J Inflamm Res. .

Abstract

Background: Both visceral fat accumulation and inflammation are commonly observed in cardiometabolic diseases (CMD). We aimed to evaluate their joint effects on CMD risk, and assessed their temporal relationship and biological interactions.

Methods: The study comprised 9559 individuals from the China Health and Retirement Longitudinal Study (CHARLS), a nationally representative cohort initiated in 2011 and completed follow-up through 2020. Visceral fat was measured by the Chinese visceral adiposity index (CVAI), and inflammation was indicated by high-sensitivity C-reactive protein (hs-CRP). Multivariate regression analyses were applied to evaluate the joint effects of CVAI and hs-CRP on CMD, including hypertension, diabetes, heart diseases, and stroke. A cross-lagged panel model was used to examine the temporal relationship. Multiplicative and additive interactions were also assessed.

Results: The mean age of the study population was 59.3 ± 9.6 years, and 5164 (54.0%) were women. Both cross-sectional and longitudinal analyses yielded consistent results that visceral fat and inflammation were individually and jointly associated with CMD. When evaluating the effect of co-exposure, the highest CMD risks were observed for individuals with high CVAI and hs-CRP levels. Compared with people with low CVAI (< 93.32 [median]) and hs-CRP (< 1 mg/L), those concurrently with high CVAI (≥ 93.32) and hs-CRP (≥ 1 mg/L) had double the increased risk of diabetes and stroke, and 40% increased risk of hypertension and heart diseases. A unidirectional temporal relationship from baseline CVAI to follow-up hs-CRP was observed, with a standardized correlation coefficient of 0.130 (P <0.001). There was significantly biological interaction between CVAI and hs-CRP, and the attributable proportion due to interaction was 19% for hypertension and 14% for diabetes.

Conclusion: The concurrent visceral fat accumulation and elevated inflammation synergistically lead to highest risks of CMD. The combined assessment of both factors may improve risk stratification and primary prevention of cardiometabolic diseases.

Keywords: additive interaction; cardiometabolic diseases; inflammation; temporal relationship; visceral fat.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow chart of sample selection.
Figure 2
Figure 2
Incidence rates of chronic diseases across groups.
Figure 3
Figure 3
Cross-lagged path analysis for CVAI and hs-CRP. The cross-lagged model was adjusted for age, sex, smoking status, drinking status, education, SBP, FPG, TC, LDL-C, Scr, UA, history of hypertension, diabetes, heart disease, and stroke.
See this image and copyright information in PMC

References

    1. O’Sullivan JW, Ashley EA, Elliott PM. Polygenic risk scores for the prediction of cardiometabolic disease. Eur Heart J. 2023;44(2):89–99. doi: 10.1093/eurheartj/ehac648 - DOI - PubMed
    1. Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023;20(7):475–494. doi: 10.1038/s41569-023-00847-5 - DOI - PubMed
    1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010 - DOI - PMC - PubMed
    1. The Writing Committee Of The Report On Cardiovascular Health And Diseases in China, and Hu S.-S. Report on cardiovascular health and diseases in china 2021: an updated summary. J Geriatr Cardiol. 2023;20(6):399–430. doi: 10.26599/1671-5411.2023.06.001 - DOI - PMC - PubMed
    1. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. doi: 10.1136/bmj.m997 - DOI - PMC - PubMed

LinkOut - more resources